Today: 11 June 2026
Browse Category

NYSE:FTV 4 February 2026

Fortive stock jumps on upbeat 2026 profit view after Q4 beat, buybacks

Fortive stock jumps on upbeat 2026 profit view after Q4 beat, buybacks

Fortive shares jumped 12.4% to $61.07 after the company forecast 2026 adjusted earnings of $2.90 to $3.00 per share, topping analyst estimates. Fourth-quarter adjusted EPS reached $0.90 on $1.12 billion in revenue, with automation segment sales up 5.3%. About 8.5 million shares traded by midafternoon. Management will present at Citi and Barclays industrial conferences later this month.
4 February 2026
·

Stock Market Today

  • AI Predicts 2026 World Cup Winner: An Unprecedented Underdog
    June 11, 2026, 5:52 PM EDT. AI models forecasting the 2026 World Cup winner are deviating from established patterns by selecting underdogs rarely deemed favorites. This shift highlights the evolving analytical approaches using artificial intelligence in sports predictions, potentially signaling a new era where data-driven insights challenge traditional expert opinions. The 2026 tournament, hosted by North America, could witness a breakthrough as AI underscores the unpredictable nature of football outcomes.

Latest articles

Bradesco Shares Rise, BBDC4 and BBD ADRs Track Brazil Market Recovery

Bradesco Shares Rise, BBDC4 and BBD ADRs Track Brazil Market Recovery

11 June 2026
Bradesco’s preferred shares jumped to R$17.67 and U.S. ADRs to $3.44 with heavy volume as Brazil’s Ibovespa surged 1.71%, spotlighting the lender after reporting a 16.1% year-over-year rise in recurring net income to R$6.811 billion in 1Q26; board and executive insiders sold non-voting shares, while the controlling group’s stake remained unchanged.
Bank of Nova Scotia Hits 52-Week High; TSX Bounces Back

Bank of Nova Scotia Hits 52-Week High; TSX Bounces Back

11 June 2026
Bank of Nova Scotia surged to a 52-week high, closing up 1.24% at C$115.27 in Toronto after announcing expanded AI adoption across its workforce and higher Q2 earnings, while the S&P/TSX Composite jumped 1.5% as financials rallied and trading volume soared above average.
Moderna Gains Almost 8% With Nasdaq Recovery; Cancer Vaccine Pipeline Still a Key Focus

Moderna Gains Almost 8% With Nasdaq Recovery; Cancer Vaccine Pipeline Still a Key Focus

11 June 2026
Moderna surged 7.94% to $49.64 as U.S. stocks rebounded sharply, with investors eyeing its mRNA cancer-vaccine pipeline after a UK trial authorization; Wall Street’s average analyst rating remains “Hold” with a $43.30 target, and BofA raised its price target to $34 citing norovirus prospects, while Moderna reported Q1 revenue of $389 million and a $1.3 billion net loss.
Go toTop